Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Has Average Price Target of $11.50 According to Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $11.50.

Several research analysts have recently weighed in on the company. Wall Street Zen cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. HC Wainwright downgraded Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday, July 31st. Royal Bank Of Canada reiterated an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. Piper Sandler reduced their price target on Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Weiss Ratings cut shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new position in Karyopharm Therapeutics in the first quarter valued at approximately $66,000. Headlands Technologies LLC acquired a new stake in Karyopharm Therapeutics during the second quarter worth approximately $118,000. OMERS ADMINISTRATION Corp acquired a new stake in Karyopharm Therapeutics during the first quarter worth approximately $108,000. Bank of New York Mellon Corp purchased a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $559,000. Finally, Royal Bank of Canada lifted its position in shares of Karyopharm Therapeutics by 4.1% during the 1st quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock worth $336,000 after buying an additional 2,399 shares during the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $0.35 on Tuesday. The stock has a market capitalization of $7.85 million, a price-to-earnings ratio of -0.03 and a beta of 1.04. Karyopharm Therapeutics has a 12 month low of $0.31 and a 12 month high of $10.99. The firm’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $5.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.37) by ($0.95). The business had revenue of $33.43 million during the quarter, compared to the consensus estimate of $32.19 million. Analysts anticipate that Karyopharm Therapeutics will post -4.70 earnings per share for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a commercial-stage biopharmaceutical company focused on discovering and developing medicines that target nuclear transport proteins involved in cancer and other serious diseases. The company’s technology platform centers on selective inhibitors of nuclear export, particularly exportin 1 (XPO1), a protein that helps regulate the movement of key molecules between a cell’s nucleus and cytoplasm.

Karyopharm’s primary product is XPOVIO (selinexor), an oral XPO1 inhibitor.